Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher

Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. Yesterday afternoon, Dermira Inc. (DERM:NASDAQ) , a biopharmaceu...
Streetwise Reports | October 21, 2019 |

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%

Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. Biopharmaceutical maker Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) yesterday announced financial and ...
Streetwise Reports | August 6, 2019 |

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...
Streetwise Reports | September 24, 2019 |

NCI Chooses Veterinary Biopharma as Select Manufacturing Contractor

The contract's meaning, terms and benefits and the California firm's near-term catalysts are discussed in an H.C. Wainwright & Co. report. In a Sept. 12 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Kindred Biosciences Inc. (KIN:NA...
Streetwise Reports | September 19, 2019 |